We Study Billionaires - The Investor’s Podcast Network TIP275: Mastermind Discussion 4Q 2019 (Business Podcast)
Dec 29, 2019
In this insightful discussion, guests Hari Ramachandra and Toby Carlisle delve into intriguing stock picks and investment strategies. They evaluate the intrinsic value of Biogen, GrafTech, Allstate, and i3 Verticals, shedding light on Mohnish Pabrai's stance on GrafTech. The conversation also covers the nuances of short selling, why put options are a safer bet, and strategies for valuing pharmaceutical companies. Risk management and navigating the insurance sector in a low-rate environment are emphasized, providing valuable insights for investors.
AI Snips
Chapters
Books
Transcript
Episode notes
i3 Verticals Short
- i3 Verticals, a payment processor, appears overvalued with high multiples due to the SaaS label.
- Toby Carlisle is shorting it anticipating a capital raise and liquidity issues will lower the stock price.
Biogen: A Potential Value Pick
- Biogen (BIIB) is undervalued with strong IP, high margins, and a good M&A track record making it a good pick.
- Consider the potential impact of settlements for impairment of intangible assets when evaluating pharmaceutical companies.
Allstate: A Stable Compounder
- Allstate, a large publicly traded property and casualty insurance company, is a stable compounder.
- It’s currently near its 52-week high, but still presents value with low multiples and insider buying, according to Stig Brodersen.
